Environmental factors such as family history of inhibitors, factor replacement therapy types and regimens, intensive FVIII therapy related to surgery or trauma [9] and immunological challenges (i.e. vaccination, viral infection) have been implicated as risks for inhibitor development [7]. Here, F8 is linked to viral infectious disease.